216 related articles for article (PubMed ID: 11080537)
1. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model.
Gotsman I; Beinart R; Alper R; Rabbani E; Engelhardt D; Ilan Y
Antiviral Res; 2000 Oct; 48(1):17-26. PubMed ID: 11080537
[TBL] [Abstract][Full Text] [Related]
2. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
3. Induction of immune tolerance toward tumor-associated-antigens enables growth of human hepatoma in mice.
Gotsman I; Israeli D; Alper R; Rabbani E; Engelhardt D; Ilan Y
Int J Cancer; 2002 Jan; 97(1):52-7. PubMed ID: 11774243
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
6. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins.
Safadi R; Israeli E; Papo O; Shibolet O; Melhem A; Bloch A; Rowe M; Alper R; Klein A; Hemed N; Segol O; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Am J Gastroenterol; 2003 Nov; 98(11):2505-15. PubMed ID: 14638356
[TBL] [Abstract][Full Text] [Related]
9. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
11. Nasal route favors the induction of CD4
Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
[TBL] [Abstract][Full Text] [Related]
12. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses to preS components after immunization of children with low doses of BioHepB.
Madalinski K; Sylvan SP; Hellström U; Mikolajewicz J; Zembrzuska-Sadkowska E; Piontek E
Vaccine; 2001 Oct; 20(1-2):92-7. PubMed ID: 11567751
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
15. Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.
Kato M; Hamada-Tsutsumi S; Okuse C; Sakai A; Matsumoto N; Sato M; Sato T; Arito M; Omoteyama K; Suematsu N; Okamoto K; Kato T; Itoh F; Sumazaki R; Tanaka Y; Yotsuyanagi H; Kato T; Kurokawa MS
J Gastroenterol; 2017 Sep; 52(9):1051-1063. PubMed ID: 28197802
[TBL] [Abstract][Full Text] [Related]
16. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
Bian Y; Zhang Z; Sun Z; Zhao J; Zhu D; Wang Y; Fu S; Guo J; Liu L; Su L; Wang FS; Fu YX; Peng H
Hepatology; 2017 Oct; 66(4):1067-1082. PubMed ID: 28445927
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model.
Mahdavi M; Mavandadnejad F; Yazdi MH; Faghfuri E; Hashemi H; Homayouni-Oreh S; Farhoudi R; Shahverdi AR
J Infect Public Health; 2017; 10(1):102-109. PubMed ID: 27026241
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
[TBL] [Abstract][Full Text] [Related]
19. The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection.
Yalcin K; Danis R; Degertekin H; Alp MN; Tekes S; Budak T
J Clin Gastroenterol; 2003 Oct; 37(4):330-5. PubMed ID: 14506391
[TBL] [Abstract][Full Text] [Related]
20. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
